—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Spyre Therapeutics Inc. (SYRE) — Quality & forensics

As of 2026-10-06 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.

The Closelooknet module scores

24 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

73.50 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

2/7 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

Continue: the SYRE chart & overview · the earnings record

FAQ · from the current data · as of 2026-10-06

Quick answers

What is Spyre Therapeutics Inc.'s Closelooknet quality reading?

The composite reads 24/100 across 7 modules, as of 2026-10-06: valuation 6, quality 2, growth 5, balance sheet 97, cash quality 6, capital allocation 6, momentum 57. Closelooknet scores are research diary readings, not ratings or investment advice.

What is Spyre Therapeutics Inc.'s Altman Z-Score?

73.50, which sits in the safe zone (above 2.99) as of 2026-10-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Spyre Therapeutics Inc.'s Piotroski F-Score?

2 of 7, as of 2026-10-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.